SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-037385
Filing Date
2022-11-10
Accepted
2022-11-10 16:11:32
Documents
68
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-10q_20220930.htm   iXBRL 10-Q 2969263
2 EX-10.1 trvi-ex101_115.htm EX-10.1 162273
3 EX-31.1 trvi-ex311_8.htm EX-31.1 14012
4 EX-31.2 trvi-ex312_9.htm EX-31.2 13986
5 EX-32.1 trvi-ex321_7.htm EX-32.1 10104
6 EX-32.2 trvi-ex322_6.htm EX-32.2 10069
  Complete submission text file 0001564590-22-037385.txt   9429354

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA trvi-20220930.xsd EX-101.SCH 54888
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE trvi-20220930_cal.xml EX-101.CAL 51858
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE trvi-20220930_def.xml EX-101.DEF 182954
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20220930_lab.xml EX-101.LAB 449372
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20220930_pre.xml EX-101.PRE 337235
62 EXTRACTED XBRL INSTANCE DOCUMENT trvi-10q_20220930_htm.xml XML 1561568
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 221377263
SIC: 2834 Pharmaceutical Preparations